DMTK vs. PMD, XGN, CNTG, BGLC, OPGN, RNLX, ENZ, PSNL, ZIVO, and CPIX
Should you be buying DermTech stock or one of its competitors? The main competitors of DermTech include Psychemedics (PMD), Exagen (XGN), Centogene (CNTG), BioNexus Gene Lab (BGLC), OpGen (OPGN), Renalytix (RNLX), Enzo Biochem (ENZ), Personalis (PSNL), ZIVO Bioscience (ZIVO), and Cumberland Pharmaceuticals (CPIX).
DermTech (NASDAQ:DMTK) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
In the previous week, Psychemedics had 2 more articles in the media than DermTech. MarketBeat recorded 6 mentions for Psychemedics and 4 mentions for DermTech. Psychemedics' average media sentiment score of -0.22 beat DermTech's score of -0.23 indicating that Psychemedics is being referred to more favorably in the news media.
Psychemedics has higher revenue and earnings than DermTech. Psychemedics is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
DermTech has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
20.5% of DermTech shares are held by institutional investors. Comparatively, 32.1% of Psychemedics shares are held by institutional investors. 5.1% of DermTech shares are held by insiders. Comparatively, 24.0% of Psychemedics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
DermTech currently has a consensus target price of $2.38, indicating a potential upside of 375.81%. Given DermTech's higher possible upside, research analysts plainly believe DermTech is more favorable than Psychemedics.
Psychemedics has a net margin of -20.23% compared to DermTech's net margin of -572.19%. Psychemedics' return on equity of -59.21% beat DermTech's return on equity.
Psychemedics received 96 more outperform votes than DermTech when rated by MarketBeat users. Likewise, 74.35% of users gave Psychemedics an outperform vote while only 57.50% of users gave DermTech an outperform vote.
Summary
Psychemedics beats DermTech on 12 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding DMTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DermTech Competitors List
Related Companies and Tools
